AURA
Generated by GPT-5-miniExpansion Funnel Raw 65 → Dedup 8 → NER 3 → Enqueued 0
| AURA | |
|---|---|
| Name | AURA |
| Type | Phenomenon |
| Field | Neurology |
| First described | Antiquity |
| Synonyms | Preictal phenomenon; sensory aura |
AURA
AURA is a transient perceptual phenomenon experienced by individuals preceding, accompanying, or independent of episodic neurological events in clinical contexts. It is observed across diverse conditions described in classical sources and modern neurology, where it functions as a prodrome, focal manifestation, or isolated sensory experience. Clinicians and researchers study AURA through neurophysiological, neuroimaging, and phenomenological approaches to understand pathophysiology, prognosis, and therapeutic implications.
Definition and Overview
In contemporary neurology AURA denotes a focal subjective sensation or sign reported by patients prior to or during transient paroxysmal events in conditions such as epilepsy, migraine, temporal lobe epilepsy, occipital lobe epilepsy, and paroxysmal disorders associated with lesions in structures like the thalamus, brainstem, cortex, and hippocampus. Descriptions span sensory, autonomic, psychic, and motor domains with reports from patients evaluated at centers including Mayo Clinic, Johns Hopkins Hospital, Massachusetts General Hospital, UCL Hospitals, and research consortia such as the International League Against Epilepsy.
History and Origins
Accounts of phenomena consistent with AURA appear in texts from Hippocrates, Galen, and later case series by clinicians in the era of Jean-Martin Charcot and John Hughlings Jackson. Systematic electroencephalography correlations emerged after the work of Hans Berger and were advanced by investigators at institutions like University College London, University of California, Los Angeles, and Harvard Medical School. Landmark descriptions in the 20th century by researchers such as William Gowers and studies involving provocative testing at facilities including National Hospital for Neurology and Neurosurgery refined nosology and linked aura phenomenology to cortical generators identified in functional studies at National Institutes of Health and international neuroimaging centers.
Types and Classifications
Clinical taxonomies classify AURA by modality and phenomenology. Sensory auras include visual phenomena localized to regions mapped by the primary visual cortex, leading to scintillating scotomas reported in cohorts at University of Oxford and Karolinska Institute. Auditory auras implicate regions studied at Royal Society-affiliated laboratories and centers like Cold Spring Harbor Laboratory for cortical processing. Olfactory and gustatory auras are often tied to medial temporal structures investigated by teams at Columbia University, University of Pennsylvania, and University of Toronto. Psychic auras—familiarity, déjà vu, jamais vu—have been characterized in research by Stanford University and in case series from Cleveland Clinic. Motor and autonomic auras overlap with data from surgical programs at Cleveland Clinic and Toronto Western Hospital.
Classification systems from bodies such as the International Headache Society and the International League Against Epilepsy categorize aura as prodromal, focal aware seizure, or isolated symptom, influencing diagnostic criteria employed at centers like Royal Melbourne Hospital and University of Sydney.
Causes and Mechanisms
Pathophysiological mechanisms proposed for AURA include focal cortical hyperexcitability, spreading cortical depression, and aberrant thalamocortical discharges. Visual auras correlate with spreading depolarization in occipital cortex mapped using techniques developed at Massachusetts General Hospital and Karolinska Institute. Limbic auras implicate epileptiform activity in hippocampal circuits studied in animal models at Max Planck Society laboratories and human intracranial recordings performed at Mayo Clinic and Mount Sinai Hospital. Vascular hypotheses relate migraine aura to oligemia demonstrated in perfusion studies at Johns Hopkins University and Imperial College London. Genetic contributions derive from investigations into channelopathies by research groups at Oxford University, Cold Spring Harbor Laboratory, and biotech collaborations with Genentech and Novartis.
Clinical Presentation and Diagnosis
Presentation varies by modality: visual scintillations and fortifications mimic descriptions documented in case series from Guy's Hospital and Addenbrooke's Hospital; olfactory hallucinations align with reports from epilepsy surgery programs such as University Hospital Bonn and Hopital de la Salpêtrière; autonomic sensations are recorded in cohorts at Royal London Hospital. Diagnosis integrates patient history, witness accounts, and multimodal testing including electroencephalography protocols refined at Rikshospitalet and magnetoencephalography used at Aarhus University Hospital and Karolinska Institute. Structural imaging with MRI sequences standardized by groups at Mayo Clinic and UCSF Medical Center identifies lesions in cortex, hippocampus, or vascular territories; functional MRI and PET studies at National Institutes of Health and Brookhaven National Laboratory can localize transient networks active during aura. Differential diagnosis includes transient ischemic attacks evaluated in stroke centers such as Johns Hopkins Hospital and psychiatric phenomena assessed at Beth Israel Deaconess Medical Center.
Treatment and Management
Management depends on etiology and setting: antiseizure medications recommended by panels from International League Against Epilepsy and therapeutic guidelines from National Institute for Health and Care Excellence are used for epileptic auras; migraine prophylaxis guided by trials at Cleveland Clinic and Massachusetts General Hospital employs agents evaluated by pharmaceutical sponsors including AstraZeneca and Eli Lilly and Company. Acute interventions—benzodiazepines in status epilepticus protocols from World Health Organization-endorsed guidelines and acute migraine therapies studied at University of Zurich—address immediate risk. Surgical options, such as resective operations reported by teams at Cleveland Clinic and University of California, San Francisco, and neuromodulation approaches developed at Medtronic and investigational programs at Duke University are considered for refractory cases. Multidisciplinary care involving specialists from National Health Service trusts, tertiary centers like Mount Sinai Hospital, and rehabilitation services optimize outcomes and risk reduction.